Recent Winners

Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Trading Lessons

Mainstream Financial News


Activision Morgan Stanley Reiterates With Overweight

March 27, 2017: Morgan Stanley reiterates Activision Blizzard Inc with Overweight rating. Morgan Stanley says eSports deep dive finds a $100 million annual rev base case, driven by content licensing/ads/sponsors. This yields minimal upside, but firms $720 million rev bull case shows how eSports could be worth $11 per ATVI share. Firms new eSports-driven $71 (Read More….)

EU Approves Amgen’s Amgevita

March 24, 2017: Amgen announced that the European Commission (EC) has granted marketing authorization for AMGEVITA (biosimilar adalimumab) in all available indications.

AMGEVITA is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic (Read More….)

Medicare Announces Criteria Covering Dexcom G5 Mobile

March 24, 2017: DexCom is pleased to announce that the U.S. Centers for Medicare & Medicaid Services (CMS) has published an article clarifying criteria for coverage and coding of the Dexcom G5 Mobile system, the only therapeutic CGM under this CMS classification. People covered by Medicare who have either Type 1 or Type 2 diabetes (Read More….)

GLD Daily Holdings Fall Rise 4.1 Tonnes to 834.4 Tonnes

March 21, 2017: StreetTracks Gold Trust SPDR Gold Trust ETF GLD daily holdings rise 4.1 tonnes to 834.4 tonnes; First rise since Mar 15th.

March 6, 2017: GLD StreetTracks Gold Trust SPDR Gold Trust ETF daily holdings fall 3.8 tonnes to 836.8 tonnes which is the lowest level since Feb 10th. This is the second (Read More….)

Teck Resources Gets Buy Rating From Berenberg

March 22, 2017: Berenberg raised Teck Resources to a Buy rating from Hold and set a price target of $27. Berenberg cites a tighter but well supplied copper market.

February 15, 2017: Teck Resources reports Q4 EPS of C$1.61 versus the C$0.03 y/y estimate. Revenue also beat coming in at C$3.56 billion versus the C$2.14 (Read More….)

Opko Receives FDA Orphan Drug Status For Oligonucleotide

March 22, 2017: OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc. announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO’s oligonucleotide-based AntagoNAT (CUR-1916) for the treatment of Dravet Syndrome. Currently, there is no approved treatment for Dravet Syndrome in (Read More….)

Medtronic Receives FDA Approval For CoreValve

March 22, 2017: Medtronic Inc announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the heels of new 30-day clinical data that (Read More….)

Mobileye May Seek Higher Offers From Other Companies

March 19, 2017: Mobileye may seek higher offers from other companies according to a report in the NY Post. Source:

**NOTE Mar 13th: Confirms to be acquired by Intel for $63.54/shr in cash valued at $15.3B; To be accretive to Intel EPS immediately

February 23, 2017: RBC reiterates Mobileye with an Outperform rating and (Read More….)

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)

Nektar Therapeutics NKTR-181 meets Primary and Secondary Endpoints in Phase 3

March 20, 2017: Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 efficacy study of NKTR-181, a first-in-class opioid analgesic. NKTR-181 is a new chemical entity (NCE) that is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction (Read More….)

Arotech Announces $9.5 Million Award From US Air Force

March 20, 2017: Arotech Corp announced that it has received a sole source $9.5M indefinite-delivery/indefinite-quantity award from the U.S. Air Force. The scope covers updates to F-16 Common Weapon Engagement Zones based upon FAAC’s Zone Acquisition Process (ZAP) technology. The contract period of performance is through March 2022. Two task orders were issued upon award (Read More….)

Amicus Therapeutics Launches Galafold in Italy

March 9, 2017: Amicus Therapeutics has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (Ministero della Salute). Galafold is now reimbursed in Italy as a therapy for long-term treatment of adults and adolescents aged 16 years and older with a (Read More….)

UBS Initiates Vertex With Buy Rating

March 9, 2017: UBS initiates Vertex Pharmaceuticals Inc with a Buy rating and a price target of $106. UBS is launching coverage of US Biotechnology with a positive outlook buoyed by (1) a better line-up of drug launches for 2017 (Biogen’s Spinraza for SMA; Regeneron’s Dupixent for atopic dermatitis, and Incyte’s Olumiant for rheumatoid arthritis), (Read More….)

NXP Semiconductors Launches World’s Smallest Single-chip SoC

March 9, 2017: NXP Semiconductors announced the world’s smallest single-chip SoC solution with the release of their MC9S08SUx microcontroller (MCU) family with an integrated 18V-to-5V LDO and MOSFET pre-driver that delivers ultra-high-voltage solution for drones, robots, power tools, DC fan, healthcare and other low-end brushless DC electric motor control (BLDC) applications. Extending the company’s S08 (Read More….)

Teligent FDA Approves Clobetasol Propionate Gel

March 8, 2017: Teligent announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Gel, 0.05%. This is Teligent’s second approval for 2017, and its thirteenth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent QuintilesIMS Health (

Institutional Traders Accumulating Low Liquidity Tecnoglass

March 7, 2017: It’s rare to see institutional investors accumulating a low liquidity stock. Generally, institutional traders stick to higher liquidity stocks so they can more easily move into or out of a stock without impact its price too much. That’s why the institutional accumulation in Tecnoglass caught my attention.

The 3-month change in institutional (

Dicks Sporting Goods Beats on Earnings and Revenue

March 07, 2017: Dicks Sporting Goods Inc reports Q4 EPS of $1.32 versus the $1.30 estimate. Revenue also beat coming in at $2.48 billion versus the $2.47 billion estimate. In 2017, Dicks Sporting Goods expects to open 43 new stores and relocate approximately 7 stores.

CEO Edward Stack said, “In 2017, we will continue to (Read More….)

Bird Flu Found on Tennessee Farm Contracted to Tyson Foods

March 05, 2017: Bird Flu said to have been found on Tennessee Farm contracted to Tyson Foods; 71,500 Birds to be culled. South Korea Agricultural Ministry bans imports of poultry from the US due to bird flu. Reportedly no people were affected in that outbreak, which was primarily of the H5N2 strain. The risk of (Read More….)

CACI International Awarded $190 Million Order Supporting DoD

March 06, 2017: CACI International announced today that it has been awarded a task order, with a potential value of $190 million, to support the Department of Defense’s Joint Service Provider (JSP) Information Technology Service Delivery Support Requirement program. The three-year, six-month task order, originally won under the Alliant contract vehicle in the fourth quarter (Read More….)

Applied Optoelectronics Announces 10 Gbps Electro-absorption Lasers

March 6, 2017: Applied Optoelectronics announced the development of Electro-absorption Modulated Lasers (EMLs) operating at a data rate of 10 Gigabits per second (Gbps).

Applied Optoelectronics’ 10 Gbps EMLs are designed specifically for 10GBASE-ZR Ethernet and cable TV (CATV) Remote PHY connectivity to enable deployment of the next-generation FTTH, telecom, and CATV networks. The lasers (Read More….)

Big 5 Sporting Goods Wedge Breakout On Heavy Institutional Buying

March 5, 2017: Big 5 Sporting Goods has formed a wedge breakout pattern on heavy institutional investors buying. The 3-month change in institutional investor ownership is an incredible 64.69%.

The company is currently paying a nice dividend of 3.88%.

February 28, 2017: Big 5 Sporting Goods met analysts estimates by reporting Q4 EPS of $0.35 (Read More….)

Aegean Marine Petroleum Swings Up On Clarksons Platou Upgrade

March 5, 2017: Aegean Marine Petroleum’s stock has done a beautiful swing up after Clarksons Platou upgraded to a Buy rating on an earnings and revenue beat.

The 3-month institutional investor ownership in Agean Marine Petroleum has increased by +8.56%.

March 1, 2017: Aegean Marine Petroleum reports Q4 EPS of $0.41 versus the $0.39 estimate. (Read More….)

Canadian National Railway Candle Over Candle On Scotia Howard Upgrade

March 5, 2017: Canadian National Railway stock has done a candle over candle reversal on a Scotia Howard upgrade. Scotia Howard Weil raised Canadian National Railway to a Sector Outperform rating from Sector Perform and set a price target of C$105.

Canadian National Railway will likely benefit from a positive outlook for potash demand. Also, (Read More….)